We therefore measured serum levels of sCD163 and CXCL5 at days 0 (immediately before the administration of nivolumab and IFN-β) and day 42, the earliest point at which severe irAEs (colitis, skin rash) caused by nivolumab might be expected to occur [29]. The gene discussed is CD163; the disease is exanthem.